| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF02208032 |
| P953 | full work available at URL | http://link.springer.com/article/10.1007/BF02208032/fulltext.html |
| http://link.springer.com/content/pdf/10.1007/BF02208032 | ||
| http://link.springer.com/content/pdf/10.1007/BF02208032.pdf | ||
| P698 | PubMed publication ID | 1676621 |
| P2093 | author name string | P. T. Dawes | |
| H. G. Taylor | |||
| E. J. Beswick | |||
| P2860 | cites work | The Journal of Rheumatology | Q7743623 |
| Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis | Q68962726 | ||
| C-reactive protein: a marker for disease activity in ankylosing spondylitis and Reiter's syndrome | Q69551610 | ||
| Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial | Q69892485 | ||
| Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial | Q69924288 | ||
| British Journal of Rheumatology | Q27709787 | ||
| C-reactive protein, ESR, and klebsiella in ankylosing spondylitis | Q33552318 | ||
| Association of inflammation with raised serum IgA in ankylosing spondylitis | Q33552748 | ||
| Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease | Q33554375 | ||
| Acute-phase proteins and serum immunoglobulins in ankylosing spondylitis | Q33554711 | ||
| Sulphasalazine in ankylosing spondylitis | Q33556616 | ||
| Further observations upon HLA-B27, Yersinia enterocolitica, and ankylosing spondylitis | Q33556748 | ||
| Significance of non-pathogenic cross reactive bowel flora in patients with ankylosing spondylitis | Q33556782 | ||
| Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis | Q33557368 | ||
| Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients | Q34289185 | ||
| Salazopyrin in rheumatoid arthritis | Q39206602 | ||
| IgA serum levels and disease activity in ankylosing spondylitis: a prospective study | Q41149938 | ||
| What is a disease modifying antirheumatic drug? | Q41269884 | ||
| HLA-B27 and the immune response to enterobacterial antigens in ankylosing spondylitis. | Q41528985 | ||
| Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate | Q42847786 | ||
| Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone | Q44592658 | ||
| In vitro susceptibility of diarrhoea producing gram negative enteric bacteria to sulfasalazine, 5-aminosalicylic acid, sulfapyridine and four quinolones. Brief report | Q50197858 | ||
| Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis. | Q54438962 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatology | Q327657 |
| P304 | page(s) | 43-48 | |
| P577 | publication date | 1991-03-01 | |
| P1433 | published in | Clinical Rheumatology | Q15754927 |
| P1476 | title | Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment | |
| P478 | volume | 10 |
| Q37534395 | A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis |
| Q37800761 | Adalimumab Improves Sleep and Sleep Quality in Patients with Active Ankylosing Spondylitis |
| Q67465264 | Ankylosing spondylitis. Current drug treatment |
| Q77120985 | Current guidelines for the drug treatment of ankylosing spondylitis |
| Q38071925 | Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. |
| Q39389171 | Oral Anaerobic Bacteria in the Etiology of Ankylosing Spondylitis |
| Q38499216 | Periodontal pathogens are likely to be responsible for the development of ankylosing spondylitis |
| Q36286209 | Pharmacological treatment of ankylosing spondylitis: a systematic review |
| Q37879332 | Prognosis, course of disease, and treatment of the spondyloarthropathies |
| Q58578681 | Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification |
| Q35554794 | Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab |
| Q39230946 | Second-line treatment in seronegative spondylarthropathies |
| Q24187791 | Sulfasalazine for ankylosing spondylitis |
| Q24244129 | Sulfasalazine for ankylosing spondylitis |
| Q41921185 | Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study |
| Q79331345 | The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases |
Search more.